Content - Brinks DEA Consulting And Compliance

Brinks DEA Consulting Content Posts

Will Ibogaine Be the New Trend in Psychedelic Therapy?

When DEA Guidance Became Law: How EO 13891 Exposed a Hidden DEA Problem

Patient-Owned Controlled Substances: A Hidden Compliance Risk for Pharmacies and Hospitals

Will the U.S. Expand Methadone Prescribing for Opioid Addiction?

DEAs New EMS Regulations Took Effect in 2026, Are You Compliant? Learn More from the Excellent Training Provided by PWW Advisory Group.

Brinks DEA Consulting Welcomes Daniel Dormont, One of the Nation’s Leading Controlled Substances Experts

Is the DEA’s non-retrievable standard too much? Maybe it’s time to change the non-retrievable standard?

Exciting Change in DEA Statutes: Pharmacy Delivery of Controlled Substances to Practitioners Expands Beyond MOUD

Important Question: What will DEA List on the Unified Agenda Spring 2026?

One DEA Number for Every Practitioner: A National Solution for Streamlined Control and Enhanced Diversion Prevention